Subscribe

Joseph Fakhoury, MD: Special Considerations in Severe Alopecia Areata

Patient Cases
Dr. Fakhoury discusses the use of systemic treatment for patients with severe alopecia areata. He highlights data from the THRIVE-AA1 and THRIVE-AA2 clinical trials, which showed effective results with deuruxilitinib vs placebo in this patient population. Additionally, he emphasizes that the indications for severe alopecia areata have expanded to those with a Severity of Alopecia Tool (SALT) score of 20 to 49 and outlined patient populations who could benefit from treatment with deuruxolitinib.

More JCAD Podcasts:

Jeffrey Cohen, MD, MPH: Treating Psoriasis in High-Impact Sites

Tina Bhutani, MD, MAS, FAAD: Use of Spesolimab for Generalized Pustular Psoriasis

Bruce Strober, MD, PhD, FAAD: Providing Care With Risankizumab in Psoriasis

James Del Rosso, DO, and David Cotter, MD, PhD: Clinical Management of Conjunctivitis, Erythema, and Arthralgia in AD

Ted Lain, MD, MBA: Long-Term Results of Deuruxolitinib for Alopecia Areata

Amy McMichael, MD: Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata

Graham Litchman, DO, MS: Understanding Long-Term Treatment Success in a Patient With Psoriasis

Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment